Evidence map›Paper›PMID 39781908›Full record

Trial reportImmunotherapy2024

Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).

Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, Angela Okragly, Zhe Sun, Chitra R Natalie, Ralph Zitnik, Kimberly Siu, Andrew Blauvelt

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Emerging Systemic Treatments for Asthma and Allergic Diseases: New Tricks, Same Dog?The journal of allergy and clinical immunology. In practice · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stanley SzeflerThe Breathing Institute and Pediatric Pulmonary and Sleep Medicine Section, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO, USA.
Jonathan CorrenDivision of Allergy and Clinical Immunology, Department of Medicine and Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jonathan I SilverbergDepartment of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Angela OkraglyEli Lilly and Company, Indianapolis, IN, USA.
Zhe SunEli Lilly and Company, Indianapolis, IN, USA.
Chitra R NatalieEli Lilly and Company, Indianapolis, IN, USA.
Ralph ZitnikValerio Consulting, LLC, Santa Barbara, CA, USA.
Kimberly SiuEli Lilly and Company, Indianapolis, IN, USA.
Andrew BlauveltBlauvelt Consulting, LLC, Lake Oswego, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLebrikizumab is an interleukin (IL)-13 inhibitor that specifically blocks IL-13 signaling. Here, we report the effects of lebrikizumab on asthma serum biomarkers in 2 phase 3 clinical studies.

methodsLAVOLTA I and LAVOLTA II are replicate, double-blind, placebo-controlled trials with 52-week placebo-controlled treatment periods that evaluated lebrikizumab 37.5- and 125-mg doses every 4 weeks. Patients were aged 18-75 years with uncontrolled asthma on stable background therapy. Biomarkers assessed included immunoglobulin E (IgE), periostin, CC motif chemokine ligand (CCL)13, and CCL17. Statistical significance was assessed for difference in fold-change for lebrikizumab versus placebo using a mixed-effects model for repeated measures.

resultsAt early time points in LAVOLTA I and II (weeks 1 and 4), decreases in periostin and CCL13 were statistically significant versus placebo (all

conclusionSignificant reductions in relevant inflammatory biomarkers were observed in the LAVOLTA I and LAVOLTA II studies.

Indexed as

Anti-Asthmatic AgentsAntibodies, MonoclonalAsthmaAdolescentAdultAgedBiomarkersCell Adhesion MoleculesChemokine CCL17Double-Blind MethodFemaleHumansImmunoglobulin EInterleukin-13MaleMiddle AgedAnti-Asthmatic AgentsAntibodies, MonoclonalBiomarkersCCL17 protein, humanCell Adhesion MoleculesChemokine CCL17Immunoglobulin EInterleukin-13lebrikizumabPOSTN protein, humanCCL13CCL17eosinophilic asthmaIgEIL-13lebrikizumabperiostinTh2 asthma

Identifiers

PMID39781908
PMCPMC11759530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.